Search results for "Zollinger-Ellison syndrome"

showing 6 items of 6 documents

Duodenal perforation as presentation of gastric neuroendocrine tumour: A case report

2020

Highlights • Gastric neuroendocrine neoplasms (g-NENs) represent the most frequent digestive NENs and are increasingly recognized thanks to diffusion of upper gastrointestinal endoscopy. • g-NENs can be sporadic or associated with multiple endocrine neoplasia type 1 (MEN-1) and present with a functional Zollinger-Ellison syndrome. • We described a case of a 60 years old Caucasian male came to emergency room with diffuse abdominal pain and leukocytosis on blood tests. • At the level of the pyloric portion we found irregularly thickened walls associated with a small fluid collection and bubbles of free air. On exploratory laparoscopy we found a large perforation (about 5 cm of size) in the fi…

medicine.medical_specialtyPerforation (oil well)Case ReportNeuroendocrine tumorsAsymptomaticGastroenterologyExploratory laparoscopyGastric perforation03 medical and health sciences0302 clinical medicineInternal medicinemedicineMultiple endocrine neoplasiaDuodenal PerforationGastrinomabusiness.industrymedicine.diseasedigestive system diseasesZollinger-Ellison syndrome030220 oncology & carcinogenesisGastric NETEmergency surgery030211 gastroenterology & hepatologySurgerymedicine.symptombusinessCarcinoid syndrome
researchProduct

Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor

2001

Awareness of important differences in the pharmacological profile of individual optical isomers of chiral drugs led to the development of esomeprazole, the S-isomer of omeprazole, a new pharmacological entity designed to improve the clinical outcome of available proton pump inhibitors in the management of acid-related disorders. The superior acid control achieved by esomeprazole is mainly due to an advantageous metabolism compared with racemate omeprazole, leading to improved bioavailability and to enhanced delivery of the drug to the gastric proton pump.

DrugPeptic Ulcermedicine.drug_classmedia_common.quotation_subjectProton-pump inhibitorPharmacologyEsomeprazolelaw.inventionZollinger-Ellison SyndromelawmedicineHumansDrug InteractionsOmeprazoleRandomized Controlled Trials as Topicmedia_commonClinical pharmacologyHepatologybusiness.industryGastroenterologyEsomeprazoleProton Pump InhibitorsAnti-Ulcer AgentsBioavailabilityProton pumpSafety profilebusinessOmeprazolemedicine.drugDigestive and Liver Disease
researchProduct

Localization of small islet-cell tumors. Preoperative and intraoperative ultrasound, computed tomography, arteriography, digital subtraction angiogra…

1985

A total of 42 islet-cell tumors were examined between 1972 and 1984. Problems of localization were only encountered in 31 tumors less than 2 cm in diameter. Of 31 small tumors, 27 were correctly localized using a combined diagnostic approach: ultrasound was successful in 12/20 tumors, CT in 9/21, angiography in 20/31, intraarterial digital subtraction angiography in 1/2, and pancreatic venous sampling in 13/16. The smallest tumor found by ultrasound and CT was 7 mm in diameter. Intraoperative ultrasound demonstrated all 9 insulinomas examined. Currently, the most useful techniques for localizing small islet-cell tumors are ultrasound, CT, and angiography. CT is particularly useful for tumor…

medicine.medical_specialtyUrologyPreoperative careZollinger-Ellison SyndromeIntraoperative PeriodPreoperative CaremedicineHumansRadiology Nuclear Medicine and imagingPancreasInsulinomaUltrasonographyRadiological and Ultrasound Technologymedicine.diagnostic_testbusiness.industryUltrasoundAngiographyGastroenterologyPhlebographyGeneral MedicineDigital subtraction angiographyAdenoma Islet Cellmedicine.diseasePancreatic Neoplasmsmedicine.anatomical_structureAngiographyInsulinomaIntraoperative PeriodRadiologyTomography X-Ray ComputedbusinessPancreasBlood samplingGastrointestinal Radiology
researchProduct

An Unusual Presentation of Zollinger-Ellison Syndrome

2013

Abstract Zollinger-Ellison syndrome is an often progressive, persistent and frequently life-threatening disease, described for the first time as characterized by ulceration of the upper jejunum, hypersecretion of gastric acid and non-beta islet cell tumors of the pancreas; this syndrome is due to the hypersecretion of gastrin. We report a case of Zollinger-Ellison syndrome presenting as severe esophagitis evolving in stenosis, which demonstrates how a delayed diagnosis may induce risk of disease spreading. In this setting new diagnostic approaches, such as somatostatin receptor scanning and positron emission tomography with 68 Ga-labeled octreotide, could be particularly useful, as well as …

Positron emission tomographyPathologymedicine.medical_specialtySettore MED/09 - Medicina InternaOctreotideZollinger-Ellison syndromePublished online: January 2013medicinelcsh:RC799-869GastrinSomatostatin receptorbusiness.industryGastroenterologyZollinger ellison. severe esophagitismedicine.diseaseZollinger-Ellison syndromemedicine.anatomical_structureOctreoscanRadionuclide therapyGastric acidlcsh:Diseases of the digestive system. GastroenterologyEsophageal stricturesPancreasbusinessEsophagitismedicine.drugCase Reports in Gastroenterology
researchProduct

Safety of high doses of somatostatin analogs in well differentiated NENs in elderly

2019

Abstract Background Neuroendocrine neoplasms (NENs) are a group of heterogeneous neoplasms which can be treated with different therapies: in well differentiated (WD) NENs analogs of somatostatin (SSA) can be used considering their proved antineoplastic and antisecretory effects. This is a multicenter study to investigate the safety of high doses (HDD) analogs of somatostatin (SSA) in WD NENs with particular attention for patients over 70 years of age. Methods We collected clinical data from 13 Italian NENs dedicated Units. Patients with WD NENs, in progression on previous treatments, included SSA, and subsequently treated with HDD-SSA, were considered. Results 170 pts were included: 61.76% …

medicine.medical_specialtyGastrinomabusiness.industryHematologyNeuroendocrine tumorsmedicine.diseaseGastroenterologyZollinger-Ellison syndromeSteatorrheaOncologyInternal medicineCholecystitisMedicinemedicine.symptombusinessInsulinomaCarcinoid syndromeMalignant Carcinoid SyndromeAnnals of Oncology
researchProduct

The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?

2018

Purpose: Analyze the role of somatostatin analogues (SSAs) in the treatment of sporadic and MEN1-related gastrinomas, trying to define whether recent trials have changed the landscape of gastrinoma therapy. Methods: We evaluate the rationale of SSA use in the treatment of gastrinomas, summarize the current literature concerning the effect of SSAs on the control of Zollinger-Ellison syndrome (ZES) and gastrinomas tumor progression and discuss their role in the most recent guidelines. Results: The medical treatment of gastrinoma and related ZES is aimed at controlling acid hypersecretion and tumor progression, in inoperable patients. The use of proton pump inhibitors (PPIs) to control the syn…

Oncologymedicine.medical_specialtyProton Pump InhibitorAntineoplastic Agents HormonalEndocrinology Diabetes and MetabolismGastrinoma; neuroendocrine tumours; somatostatin; somatostatin analogues; endocrinology; diabetes and metabolism; endocrinologyNeuroendocrine tumorssomatostatinOctreotideSomatostatin analogueSettore MED/13 - EndocrinologiaZollinger-Ellison Syndrome03 medical and health sciencesendocrinology0302 clinical medicineInternal medicineNeuroendocrine tumourmedicineHumansProgression-free survivaldiabetes and metabolismGastrinomaMedical treatmentsomatostatin analoguesbusiness.industryDisease progressionPancreatic NeoplasmProton Pump Inhibitorsmedicine.diseasedigestive system diseasesZollinger-Ellison syndromePancreatic NeoplasmsEndocrinologySomatostatinTreatment OutcomeTumor progression030220 oncology & carcinogenesisGastrinoma030211 gastroenterology & hepatologyneuroendocrine tumoursbusinessHuman
researchProduct